|Grant Number:||5R01CA064247-09 Interpret this number|
|Primary Investigator:||Ho, Gloria|
|Organization:||Albert Einstein College Of Medicine|
|Project Title:||Spontaneous Regression Biomarkers in Cervix Dysplasia|
DESCRIPTION: (Adapted from the Investigator's Abstract) The applicants propose to continue an ongoing prospective study in which women with CIN I or II are recruited and followed in order to identify biomarkers associated with regression of CIN. The following factors will be assessed: (1) humoral immune response to virus-like particles (VLPs) of HPV types 6, 16, 18, 31, 53, and 58, (2) cell-mediated immunity (CMI) to HPV 16 E6 and E7 peptides, (3) class II HLA DQB1 and DRB1 alleles, (4) plasma ascorbic acid level, and (5) red blood cell (RBC) folate level. Continuation of this existing study is necessary to increase sample size and thus provide sufficient statistical power to better understand how these host factors may interact to influence the outcome of CIN. Women will be recruited from the colposcopy clinics of 3 hospitals associated with the Albert Einstein College of Medicine and followed at 3-month intervals by Pap smear and colposcopy for 12 months. At this point, an endpoint biopsy will be performed to determine whether CIN lesions are present ('persistence') or absent ('regression'). At each visit, cervico-vaginal lavage specimens will be collected for HPV DNA analyses by Southern blot and polymerase chain reaction (PCR). Blood will be collected for HPV VLP serology, T cell proliferative response (CMI) assay, plasma reduced ascorbic acid by high pressure liquid chromatography, and RBC folate levels by immunoassay. DNA typing of class II HLA alleles by PCR will be performed using blood collected at baseline. Associations between these factors and regression of CIN will be assessed by appropriate univariate and multivariate analyses.
Variability of serum levels of tumor necrosis factor-alpha, interleukin 6, and soluble interleukin 6 receptor over 2 years in young women.
Authors: Ho GY, Xue XN, Burk RD, Kaplan RC, Cornell E, Cushman M
Source: Cytokine, 2005 Apr 7;30(1), p. 1-6.
Polymorphism of the insulin gene is associated with increased prostate cancer risk.
Authors: Ho GY, Melman A, Liu SM, Li M, Yu H, Negassa A, Burk RD, Hsing AW, Ghavamian R, Chua SC Jr
Source: Br J Cancer, 2003 Jan 27;88(2), p. 263-9.
Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
Authors: Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M, Albert Einstein Cervix Dysplasia Clinical Consortium
Source: Cancer Epidemiol Biomarkers Prev, 2002 May;11(5), p. 483-8.
Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate cancer families.
Authors: Ho GY, Knapp M, Freije D, Nelson WG, Smith JR, Carpten JD, Bailey-Wilson JE, Beaty TH, Petersen G, Xu J, Kamensky V, Walsh PC, Isaacs WB
Source: Int J Cancer, 2002 Apr 20;98(6), p. 938-42.